Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-02413873 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-02413873 | EXPERIMENTAL | PF-2413873 active treatment |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| PF-02413873 100 mg QD | DRUG | 100 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 1500 mg QD | DRUG | 1500 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 20 mg QD | DRUG | 20 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 500 mg QD | DRUG | 500 mg of PF-02413873 oral suspension once daily for 14 days |
| PF-02413873 Placebo | DRUG | PF-0241383 Placebo once daily for 14 days |
Inclusion Criteria: * Healthy women of childbearing potential with a regular menstrual cycle Exclusion Criteria: * Evidence or history of any major disease * Pregnant or nursing women * Requirement for chronic medication
PF-02413873 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for endometriosis, a condition in which tissue similar to the uterine lining grows outside the uterus. It is in Phase 1 clinical development and has been studied in healthy young women. PF-02413873 is also referred to as PF-02413873 100 mg QD.
PF-02413873 is being developed for endometriosis, an endocrine condition. The clinical program has evaluated its effects on sex hormone levels in healthy young women rather than in patients with confirmed endometriosis. It remains investigational and has not been approved for any use.
PF-02413873 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States and Belgium.
PF-02413873 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial has been completed, and no trials are currently active.
PF-02413873 has been studied in one completed Phase 1 trial, NCT00800618, titled a study to investigate how the body handles multiple doses of PF-0243873 and the effect of PF-02413873 on sex hormone levels in healthy young women. It enrolled 42 participants, was randomized, double blind, and placebo controlled, and took place in the United States and Belgium.